Update on Sitosterolemia and Atherosclerosis

Nenhuma Miniatura disponível
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
CURRENT MEDICINE GROUP
Autores
Citação
CURRENT ATHEROSCLEROSIS REPORTS, v.25, n.5, p.181-187, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose of ReviewThe purpose of this review was to summarize important and updated information on sitosterolemia. Sitosterolemia is an inherited lipid disorder consisting of high levels of plasma plant sterols. This sterol storage condition is caused by biallelic loss-of-function genetic variants in either ABCG5 or ABCG8, leading to increased intestinal absorption and decreased hepatic excretion of plant sterols. Clinically, patients with sitosterolemia usually exhibit xanthomatosis, high levels of plasma cholesterol, and premature atherosclerotic disease, but presentation can be highly heterogeneous. Therefore, recognition of this condition requires a high level of suspicion, with confirmation upon genetic diagnosis or through measurement of plasma phytosterols. Treatment of sitosterolemia with both a plant sterol-restricted diet and the intestinal cholesterol absorption inhibitor ezetimibe can reduce efficiently the levels of plasma plant sterols, consisting in the first-line therapy for this disease.Recent FindingsSince hypercholesterolemia is often present in individuals with sitosterolemia, it is important to search for genetic variants in ABCG5 and ABCG8 in patients with clinical criteria for familial hypercholesterolemia (FH), but no variants in FH implicated genes. Indeed, recent studies have suggested that genetic variants in ABCG5/ABCG8 can mimic FH, and even when in heterozygosis, they may potentially exacerbate the phenotype of patients with severe dyslipidemia.Sitosterolemia is a genetic lipid disorder characterized by increased circulating levels of plant sterols and clinically manifested by xanthomatosis, hematologic disorders, and early atherosclerosis. Awareness about this condition, a rare, but commonly underdiagnosed and yet treatable cause of premature atherosclerotic disease, is imperative.
Palavras-chave
Sitosterolemia, Plant sterols, Cholesterol, Hypercholesterolemia, Atherosclerosis, Xanthomas
URI
https://observatorio.fm.usp.br/handle/OPI/58333
Referências
  1. Bao LP, 2006, J BIOL CHEM, V281, P33635, DOI 10.1074/jbc.M606339200
  2. BELAMARICH PF, 1990, PEDIATRICS, V86, P977
  3. BHATTACHARYYA AK, 1974, J CLIN INVEST, V53, P1033, DOI 10.1172/JCI107640
  4. Brinton EA, 2018, J CLIN LIPIDOL, V12, P152, DOI 10.1016/j.jacl.2017.10.013
  5. Escolà-Gil JC, 2014, CURR ATHEROSCLER REP, V16, DOI 10.1007/s11883-014-0424-2
  6. Izar MCD, 2021, ARQ BRAS CARDIOL, V117, P782, DOI 10.36660/abc.20210788
  7. Ference BA, 2017, EUR HEART J, V38, P2459, DOI 10.1093/eurheartj/ehx144
  8. GREGG RE, 1986, J CLIN INVEST, V77, P1864, DOI 10.1172/JCI112513
  9. Hansel B, 2014, ATHEROSCLEROSIS, V234, P162, DOI 10.1016/j.atherosclerosis.2014.02.030
  10. Katayama S, 2003, INTERNAL MED, V42, P591, DOI 10.2169/internalmedicine.42.591
  11. Kolovou G, 1996, EUR HEART J, V17, P965
  12. KWITEROVICH PO, 1981, LANCET, V1, P466
  13. Lu KM, 2001, AM J HUM GENET, V69, P278, DOI 10.1086/321294
  14. Lütjohann D, 2008, INT J CLIN PRACT, V62, P1499, DOI 10.1111/j.1742-1241.2008.01841.x
  15. Mach F, 2019, ATHEROSCLEROSIS, V290, P140, DOI [10.1016/j.atherosclerosis.2019.08.014, 10.1093/eurheartj/ehz455]
  16. Bastida JM, 2021, PLATELETS, V32, P573, DOI 10.1080/09537104.2020.1779926
  17. MIETTINEN TA, 1980, EUR J CLIN INVEST, V10, P27, DOI 10.1111/j.1365-2362.1980.tb00006.x
  18. Musliner T, 2008, INT J CLIN PRACT, V62, P995, DOI 10.1111/j.1742-1241.2008.01786.x
  19. NGUYEN LB, 1991, J LIPID RES, V32, P1941
  20. Niu DM, 2010, J INHERIT METAB DIS, V33, P437, DOI 10.1007/s10545-010-9126-2
  21. Othman RA, 2013, ATHEROSCLEROSIS, V231, P291, DOI 10.1016/j.atherosclerosis.2013.09.038
  22. PARSONS HG, 1995, CLIN INVEST MED, V18, P389
  23. Peterson Amy L, 2020, JACC Case Rep, V2, P646, DOI 10.1016/j.jaccas.2019.12.041
  24. Plat J, 2001, J LIPID RES, V42, P2030
  25. Rubis B, 2008, BRIT J NUTR, V100, P1183, DOI 10.1017/S0007114508981423
  26. Salen G, 2004, CIRCULATION, V109, P966, DOI 10.1161/01.CIR.0000116766.31036.03
  27. SALEN G, 1985, J LIPID RES, V26, P1126
  28. Sudhop T, 2002, CIRCULATION, V106, P1943, DOI 10.1161/01.CIR.0000034044.95911.DC
  29. Tada H, 2021, J ATHEROSCLER THROMB, V28, P791, DOI 10.5551/jat.RV17052
  30. Tada H, 2019, CIRC J, V83, P1917, DOI 10.1253/circj.CJ-19-0317
  31. Tada H, 2018, J ATHEROSCLER THROMB, V25, P783, DOI 10.5551/jat.RV17024
  32. Tada MT, 2022, CIRC-GENOM PRECIS ME, V15, DOI 10.1161/CIRCGEN.121.003390
  33. Tsubakio-Yamamoto K, 2010, J ATHEROSCLER THROMB, V17, P891, DOI 10.5551/jat.4614
  34. Tzavella E, 2017, J CLIN LIPIDOL, V11, P1095, DOI 10.1016/j.jacl.2017.04.116
  35. Xia Y, 2022, J CLIN LIPIDOL, V16, P40, DOI 10.1016/j.jacl.2021.11.015
  36. Xu LY, 2020, AM J CARDIOL, V125, P1312, DOI 10.1016/j.amjcard.2020.01.048
  37. Yamada Yoshihiro, 2021, CJC Open, V3, P1085, DOI 10.1016/j.cjco.2021.04.008
  38. Yoo Eun-Gyong, 2016, Ann Pediatr Endocrinol Metab, V21, P7, DOI 10.6065/apem.2016.21.1.7

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/13